
Total revenues
 |
$6.3 billion
 |
$5.5 billion
 |
14%
 |
|
Operating earnings, excluding development**
|
$371.1 million |
$312.8 million |
19% |
|
Net income
|
$389.5 million |
$394.9 million |
(1%) |
|
Per share results:
|
|
|
|
|
Operating earnings**
|
$0.65 |
$0.57 |
14% |
|
Favorable development of prior-period health care cost estimates
|
(0.01) |
(0.05) |
|
|
Operating earnings, excluding development**
|
$0.64 |
$0.52 |
23% |
|
Net income
|
$0.67 |
$0.65 |
3% |
|
Weighted average common shares (diluted)
|
584.2 million |
607.0 million |
|
* Restated for FAS123R and stock split. Refer to footnote 2 at the end of this press release.
** For a full description of operating earnings and per-share operating earnings, refer to footnote 1 at the end of this press
|